1

Discrimination of SARS-Cov 2 and arboviruses (DENV, ZIKV and CHIKV) clinical features using machine learning techniques: a fast and inexpensive clinical screening for countries simultaneously affected by both diseases

João Daniel S. Castro^{a, b*}

joaodasc@gmail.com

^a Universidade do Estado da Bahia, Departamento de Ciências Exatas e da Terra, Programa de Pós-Graduação em Química Aplicada, Salvador, BA, Brazil,

^b Secretária da Educação do Estado da Bahia, Centro Administrativo da Bahia - CAB, Salvador, BA, Brazil

Abstract

SARS-Cov-2 (Covid-19) has spread rapidly throughout the world, and especially in tropical countries already affected by outbreaks of arboviruses, such as Dengue, Zika and Chikungunya, and may lead these locations to a collapse of health systems. Thus, the present work aims to develop a methodology using a machine learning algorithm (Support Vector Machine) for the prediction and discrimination of patients affected by Covid-19 and arboviruses (DENV, ZIKV and CHIKV). Clinical data from 204 patients with both Covid-19 and arboviruses obtained from 23 scientific articles and 1 dataset were used. The developed model was able to predict 93.1% of Covid-19 cases and 82.1% of arbovirus cases, with an accuracy of 89.1% and Area under Roc Curve of 95.6%, proving to be effective in prediction and possible screening of these patients, especially those affected by Covid-19, allowing early isolation.

Keywords: Coronavirus; Covid-19; Arbovirus; Machine Learning; Clinical Features; Dengue; Zika; Chikungunya

Introduction

- 1 In December 2019, a series of pneumonia cases of unknown cause emerged among
- 2 visitors to a wet market in the city of Wuhan, Hubei (China). Genetic sequencing of
- 3 samples from the respiratory tract of these patients identified a new type of Coronavirus,

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

2

4 called (2019-nCoV) [1], which since the outbreak, has affected more than 1 million
5 people and totals 60,000 deaths worldwide [2,3].

6 Covid-19 produces a systemic respiratory disease that can progress to severe pneumonia
7 in approximately 16% of cases [4]. Sepsis is the most frequent complication, followed by
8 respiratory failure, acute respiratory distress (ARDS), heart failure and septic shock [5].

Concomitantly with the Covid-19 outbreak, tropical countries have faced successive 9 outbreaks of arboviruses, such as Dengue (DENV), Zika (ZIKV) and Chikungunya 10 (CHIKV), presenting themselves as a challenge to the health systems of these countries. 11 Arboviruses are diseases caused by viruses transmitted to humans through the bites of 12 infected blood-sucking arthropods, predominantly Aedes mosquitoes [6], and their 13 clinical manifestations can vary from mild and undifferentiated febrile disease to 14 neurological, joint and hemorrhagic febrile syndromes [7]. In addition, it is observed that 15 there is a low probability of predicting a possible outbreak [8], which may surprise health 16 systems that, today, are saturated due to the Covid-19 pandemic. 17

The imminence of a syndemic state between Covid-19 and arboviruses (mainly Dengue) 18 19 has been shown to be a concern of researchers from Latin American countries [9,10]. 20 Even though it has not yet reported cases of co-infection, your treatment may be adversely 21 affected, since the spectrum of drugs does not seem compatible [11]. Associated with this, 22 researchers have reported a false positive diagnosis for Dengue in situations in which patients are affected by the SARS-CoV-2 virus [12,13], even though there was no 23 genomic similarity between the viruses [14], which can make the diagnosis of these 24 25 diseases even more difficult.

Brazil has historically faced cycles of arbovirus epidemics throughout its territory, with Dengue being the most prevalent arbovirus [15]. According to the most recent Brazilian epidemiological bulletin, until now (ie, April 06, 2020) approximately 500 thousand cases of arboviruses have been reported (DENV, ZIKV, CHIKV), 96% of which are associated with dengue, 2.73% Chikungunya and 0.33% to Zika [16], compared to 9506 cases of Covid-19 (until April 3) [17].

Thus, in order to optimize resources and care for patients, as well as to enable effective screening, allowing isolation and early management, biomarkers (obtained through blood counts at admission) can be effective in predicting the degree of severity of disease. Studies indicate that Covid-19 causes Lymphocytopenia [4] and Thrombocytopenia [18],

3

36 while arboviruses can cause Leukopenia, Lymphohistiocytosis and mild37 Lymphocytopenia [19–22].

Therefore, based on the clinical data of patients affected by Covid-19 or Arboviruses (DENV, ZIKV and CHIKV), this study aims to build a predictive model using machine learning algorithms, in order to screen and diagnose patients in case a possible syndemic state. It is also intended to share clinical data by the medical community about diseases of global circulation, in order to mitigate their impacts.

43

44 2 Materials and Methods

45

An electronic search was performed in the databases of Periódicos CAPES (portal of the 46 Brazilian development agency CAPES, which aggregates numerous publishers of 47 scientific journals), Google Scholar, Google Dataset and Science Direct, using the 48 keywords, "Clinical features" OR "White blood cells count "OR" Haemogram "AND" 49 coronavirus 2019 "OR" COVID-19 "OR" 2019-nCoV "OR" SARS-CoV-2". To search 50 for clinical data related to arboviruses, the terms "Clinical features" OR "White blood 51 cells count" OR "Haemogram" AND "Dengue" OR "Zika" OR "Chikungunya" were 52 used. A Dataset containing clinical data from Brazilian patients Positive for SARS-CoV-53 2 was also added to the data set, made available by Hospital Israelita Albert Einstein [23]. 54

The papers were chosen according to the criteria of: analysis of the abstract, title and body of the text, excluding works that presented only the average of the data obtained for a group of patients or that did not present the patients' blood count. Thus, 23 scientific papers were selected, all of which were written in English.

This study was carried out in accordance with the Declaration of Helsinki and inaccordance with the terms of local legislation.

The predictive model was built using the open-source software Orange (v. 3.20.1) [24].

Before the implementation of the algorithm, the data were normalized (center by mean)
and then submitted to the detection of outliers (abnormal data), using covariance
assessment.

The input data for the training of the algorithm were the White Blood Cells count (WBC)and the Lymphocite count, available in the articles, and the classes used for the prediction

4

were Covid-19 and Arboviruses. The type of algorithm used was SVM with Cost 67 regression (c) = 1.50, Kernel type RBF (g = 1.04) and the following optimization 68 parameters: numerical tolerance = 0.005, without iteration limit. 69

The model was trained using the data and validated using the cross-validation 70 methodology, with k-fold =20. The validation method consists of dividing the data set 71 into k parts, using k-1 parts for modeling (training) and the remaining part for testing. In 72 this model the data set was tested twenty times, each one with a different fold from 73 74 dataset.

75 The idea behind this type of algorithm is to map the data, transposing it into a high 76 dimensional space in which hyperplanes separate the data into subgroups (clusters) 77 according to their characteristics, allowing the classification problem to be more easily solved [25]. 78

79 The model developed is available in supplementary materials.

3. Results and discussion 80

81

82 3.1 Characteristics of the included studies

83

The detailed characteristics of this study are found in the Dataset available as 84 supplementary material. Data from 204 patients were used in total, and after detecting 85 outliers, 120 patients remained positive for SARS-CoV-2 and 67 patients with 86 arboviruses (DENV, ZIKV and CHIKV), in a wide age group and of both sexes, totaling 87 187 patients. 88

89

The parameters used for the evaluation and screening was the existence / prevalence of 90 91 Leukopenia and Lymphohistiocytosis / Lymphocytopenia, based on what was previously 92 reported in the literature. Tables 1 and 2 summarize the data found in the literature. It is worth noting that the dataset provided by Hospital Israelita Albert Einstein [23] was 93 94 already normalized, and therefore it is not shown in the data set in the tables below.

95 Table 1. Clinical features of patients affected by Covid-19

Número de	Disease	WBC (10 ⁹ /L)	Lymphocites	Observation	Reference
Pacientes			$(10^{9}/L)$		

9	Covid-19	7.70 (5.07 -10.61)	1.18 (0.46-1.59)	Pregnant	[26]
5	Covid-19	7.6 (5.03 - 10.76)	0.74 (0.63 - 0.92)	Hemodialysis	[27]
5	Covid-19	8.75 (6.12 - 12,4)	1.42 (0.84-2.46)	Asymptomatic	[28]
5	Covid-19	5.68 (4.4 - 7.1)	1.56 (1.3- 1.7)	Reactivation	[29]
6	Covid-19	6.13 (4.3 – 11.4)	1.7 (0.6 – 2.7)	-	[30]
4	Covid-19	5.49 (4.23 - 6.84)	1.19 (0.42 - 1.98)	-	[31]
2	Covid-19	5.76 (4.37 - 7.16)	1.03 (0.88 – 1.19)	-	[32]
1	Covid-19	10.6	0.86	Pregnant	[33]
Total = 37		Mean = 7,06	Mean = 1,27		

97	Table 2. Clinical feature	s of patients affect	ted by arboviruses	(DENV, ZIKV and CHIKV)
----	---------------------------	----------------------	--------------------	------------------------

Número de	Disease	WBC (10 ⁹ /L)	Lymphocites	Observation	Reference
Pacientes			$(10^{9}/L)$		
1	Zika	2.28	0.83	Liver injury	[34]
1	Zika	6.10	1.0	-	[35]
1	Zika	4.90	1.42	-	[36]
12	Zika	5.96 (3.78 -10.13)	2.64 (0.39 - 7.09)	-	[37]
1	Zika	3.65	0.47	-	[38]
1	Zika	3.10	1.55	-	[39]
1	Chikungunya	3.10	0.7	-	[40]
14	Chikungunya	7.32 (3.00 -13.00)	3.44 (1.30 - 7.54)	Children	[41]
1	Chikungunya	15.7	6.09	-	[42]
1	Chikungunya	19.1	1.01	Erysipelas	[43]
3	Chikungunya	28.9 (21.8 - 35.1)	1.2 (0.7-1.2)	Fatal cases	[44]
1	Chikungunya	3.2	1.09	-	[45]
5	Zika/Dengue	3.65 (1.24 - 6.3)	0.96 (0.39 -1.84)	Coinfection	[46]
1	Dengue	1.60	0.93	-	[47]
40	Dengue	7.16 (4.43 - 11.9)	4.87 (1.90 - 6.70)	_	[48]
Total = 84		Média = 7,48	Média = 3,55		

3.2 Model assessment

		Predicted		
		Arboviruses	Covid -19	Σ
Actual	Arboviruses	82.1 %	6.9 %	63
	Covid -19	17.9 %	93.1 %	120
	Σ	67	116	183

Figure 1. Confusion Matrix for classification test using an SVM machine learning algorithm

6

The results of a classification can be represented as a matrix called a confusion matrix, a
square matrix (G x G) whose rows and columns represent the experimental and predicted
data respectively [49].

The matrix shows that the model was able to predict more than 90% of Covid-19 cases
and 82.1% of cases of arboviruses, based on clinical data obtained in the literature. The
developed model also has an Area under Roc Curve (AUC) of 0.956, an accuracy of 0.891
and an precision of 0.893.

Lymphocytopenia is a clinical condition observed in patients with SARS-CoV-2,
regardless of gender, age and / or pre-existence of comorbidities [50–52].

113 This condition allowed the correct classification of most of the observed cases. The 114 classification error of individuals affected by arboviruses is also reported by Yan and 115 collaborators, when describing two clinical pictures of SARS-Cov-2 as false positives for 116 Dengue (DENV) [12], showing the urgency in the development of more accurate 117 methodologies.

Leukopenia presents to patients with arboviruses (DENV, ZIKV and CHIKV) in medium to intense degrees, according to the PAHO (Pan-American Health Organization) classification [53], and also presented in clinical studies [54,55]. Associated with this, some patients may experience lymphohistiocytosis [56–58]. These characteristics allowed the correct classification of 82.1% of the cases.

123 Cases misclassified totaling 10.93% of cases and are presented in Table 3:

- 124
- 125

Table 1. Misclassified cases

WBC (10 ⁹ /L)	Lymphocite	Actual	Predicted
	(10 ⁹ /L)		
5.6	2.2	Covid -19	Arboviruses
8.24	2.46	Covid -19	Arboviruses
6.48	1.98	Covid -19	Arboviruses
4.2	0.7	Covid -19	Arboviruses
4.23	1.28	Covid -19	Arboviruses
6.5	2.8	Covid -19	Arboviruses
11.4	2.7	Covid -19	Arboviruses

7

7.63	2.83	Covid -19	Arboviruses
4.4	1.08	Covid -19	Arboviruses
4.4	1.7	Covid -19	Arboviruses
4.3	1.2	Covid -19	Arboviruses
4.5	1.4	Covid -19	Arboviruses
7.56	2.12	Arboviruses	Covid -19
9.6	1.3	Arboviruses	Covid -19
7.54	1.66	Arboviruses	Covid -19
6.3	1.84	Arboviruses	Covid -19
6.1	1	Arboviruses	Covid -19
4.28	0.39	Arboviruses	Covid -19
5.86	1.76	Arboviruses	Covid -19
9.7	1.9	Arboviruses	Covid -19


126

127 From the analysis of table 3 and figure 2, we can find the factors that allow the erroneous classification of patients: half of the patients affected by Covid-19 who have WBC values 128 129 $(\cong 5)$ associated with low values of lymphocytes (> 2) are classified as having arboviruses; while the other half is classified according to the high value of lymphocytes 130

Patients affected by arboviruses who have lymphocytopenia (lymphocytes ≤ 2) and 131 132 without leukopenia are classified as having Covid-19.



8



135 Figure 2. WBC x Lymphocite count plot for patients classified incorrectly. The caption of each patient 136 indicates the disease to which it is affected, the symbols indicate the predicted illness

137



139

140 The model developed was effective in discriminating based on clinical data between patients affected by Covid-19 and patients affected by arboviruses (DENV, ZIKV, 141 142 CHIKV), being able to predict 93.1% of the cases of SARS-CoV-2 and 82.1% of cases of arboviruses. Even though it presented a not very satisfactory result for arboviruses, the 143 model allows the screening of patients with Coronavirus (contagious), thus speeding up 144 the isolation and hospitalization procedures. 145

146 Because it was developed using free software, this model can be used in public health 147 systems in countries in the event of a simultaneous outbreak of arboviruses and Covid-19, minimizing the impacts of a possible collapse of the health system. 148

149

150 Acknowledgements

1		

1	с	1
- Т	Э	Τ.

The author thanks the collaboration of doctors Marjorie Lobo and Tainá Cajazeira and 152 153 the researcher Luane Barbosa for the review of this work. 154 References 155 156 C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. 157 [1] 158 Gu, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet. (2020) 497-506. doi:10.1016/S0140-6736(20)30183-5. 159 World Health Organization, Coronavirus disease 2019 (COVID-19) Situation 160 [2] Report - 76, 2019 (2020). https://www.who.int/docs/default-161 source/coronaviruse/situation-reports/20200405-sitrep-76-covid-162 19.pdf?sfvrsn=6ecf0977_4. 163 E. Dong, H. Du, L. Gardner, An interactive web-based dashboard to track 164 [3] 165 COVID-19 in real time, Lancet Infect. Dis. 3099 (2020) 19-20. doi:10.1016/S1473-3099(20)30120-1. 166 167 [4] W. Guan, Z. Ni, Y. Hu, W. Liang, C. Ou, J. He, L. Liu, H. Shan, C. Lei, D.S.C. Hui, B. Du, L. Li, G. Zeng, K. Yuen, R. Chen, C. Tang, T. Wang, P. Chen, J. 168 Xiang, S. Li, J. Wang, Z. Liang, Y. Peng, L. Wei, Y. Liu, Y. Hu, P. Peng, J. 169 Wang, J. Liu, Z. Chen, G. Li, Z. Zheng, S. Qiu, J. Luo, C. Ye, S. Zhu, Clinical 170 Characteristics of Coronavirus Disease 2019 in China, N. Engl. J. Med. (2020) 1-171 13. doi:10.1056/NEJMoa2002032. 172 F. Zhou, T. Yu, R. Du, G. Fan, Y. Liu, Z. Liu, J. Xiang, Y. Wang, B. Song, X. 173 [5] 174 Gu, L. Guan, Y. Wei, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, 175 Lancet. 395 (2020) 1054–1062. doi:10.1016/S0140-6736(20)30566-3. 176 A. Wilder-smith, D.J. Gubler, S.C. Weaver, T.P. Monath, D.L. Heymann, T.W. 177 [6] Scott, Epidemic arboviral diseases : priorities for research and public health, 178 Lancet Infect. Dis. 3099 (2016) 1-6. doi:10.1016/S1473-3099(16)30518-7. 179

180 181 182	[7]	A.P.B. Von Zuben, Maria Rita Donalisio, André Ricardo Ribas Freitas, Arboviroses emergentes no Brasil : desafios para a clínica e implicações para a saúde pública, Rev. Saude Publica. 51 (2017) 10–15.
183 184 185 186	[8]	D. Musso, A.J. Rodriguez-morales, J.E. Levi, D.J. Gubler, Personal View Unexpected outbreaks of arbovirus infections : lessons learned from the Pacific and tropical America, Lancet Infect. Dis. 3099 (2018) 1–7. doi:10.1016/S1473- 3099(18)30269-X.
187 188 189 190 191	[9]	 A.J. Rodriguez-Morales, V. Gallego, J.P. Escalera-Antezana, C.A. Méndez, L.I. Zambrano, C. Franco-Paredes, J.A. Suárez, H.D. Rodriguez-Enciso, G.J. Balbin-Ramon, E. Savio-Larriera, A. Risquez, S. Cimerman, COVID-19 in Latin America: The implications of the first confirmed case in Brazil, Travel Med. Infect. Dis. (2020) 101613. doi:10.1016/j.tmaid.2020.101613.
192 193 194 195	[10]	M. Saavedra-Velasco, C. Chiara-Chilet, R. Pichardo-Rodriguez, A. Grandez- Urbina, F. Inga-Berrospi, Coinfección entre dengue y COVID-19: Necesidad de abordaje en zonas endémicas, Rev. Fac. Cienc. Med. Cordoba. 77 (2020) 52–54. doi:10.31053/1853.0605.v77.n1.28031.
196 197 198 199	[11]	J. Navarro, J. Arrivillaga-henríquez, J. Salazar-loor, A.J. Rodriguez-morales, COVID-19 and dengue, co-epidemics in Ecuador and other countries in Latin America: Pushing strained health care systems over the edge, Travel Med. Infect. Dis. (2020) 101656. doi:10.1016/j.tmaid.2020.101656.
200 201 202 203	[12]	G. Yan, C.K. Lee, L.T.M. Lam, B. Yan, Y.X. Chua, A.Y.N. Lim, K.F. Phang, G. Sen Kew, H. Teng, C.H. Ngai, L. Lin, R.M. Foo, S. Pada, L.C. Ng, P.A. Tambyah, Covert COVID-19 and false-positive dengue serology in Singapore, Lancet Infect. Dis. 3099 (2020) 30158. doi:10.1016/S1473-3099(20)30158-4.
204 205	[13]	B. joob, V. Wiwanitkit, COVID-19 can present with a rash and be mistaken for Dengue, J. Am. Acad. Dermatol. (2020) 19–22. doi:10.1016/j.jaad.2020.03.036.
206 207 208	[14]	Y. Li, B. Liu, J. Cui, Z. Wang, Y. Shen, Y. Xu, K. Yao, Y. Guan, Similarities and Evolutionary Relationships of COVID-19 and Related Viruses, (2020). http://arxiv.org/abs/2003.05580.
209 210	[15]	V.I. Avelino-Silva, J.F. Ramos, Arboviroses e políticas públicas no Brasil Arboviruses and public policies in Brazil, Rev. Ciências Em Saúde. 7 (2017) 1–2.

211		doi:10.21876/rcsfmit.v7i3.675.
212 213 214 215 216	[16]	Brasil, Monitoramento dos casos de arboviroses urbanas transmitidas pelo Aedes Aegypti (dengue, chikungunya e zika), Semanas Epidemiológicas 1 a 13, 2020, Bol. Epidemiológico 14. 51 (2020) 1–34. https://www.saude.gov.br/images/pdf/2020/April/03/Boletim-epidemiologico- SVS-14.pdf.
217 218 219 220	[17]	Brasil, Doença pelo Coronavírus 2019, Bol. Epidemiológico Do Cent. Operações Emergência Em Saúde Pública 06. 06 (2020) 1–23. https://portalarquivos.saude.gov.br/images/pdf/2020/April/03/BE6-Boletim- Especial-do-COE.pdf.
221 222 223	[18]	G. Lippi, M. Plebani, B. Michael, Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections : A meta -analysis, Clin. Chim. Acta. 506 (2020) 145–148. doi:10.1016/j.cca.2020.03.022.
224 225 226 227	[19]	T. Elias, C. Fernanda, A. Francesli, N. Reis, N. Santos, M. Lima, E. Márcia, S. Cabrera, I. Nuremberg, F. Rodrigues, L. Elisa, A. Antônio, Clinical , laboratory and virological data from suspected ZIKV patients in an endemic arbovirus area, J. Clin. Virol. 96 (2017) 20–25. doi:10.1016/j.jcv.2017.09.002.
228 229	[20]	M. Kapdi, I.R.A. Shah, Dengue and haemophagocytic lymphohistiocytosis, Scand. J. Infect. Dis. (2012) 708–709. doi:10.3109/00365548.2011.652667.
230 231	[21]	SC.J. Wæhre T, Maagard A, Tappe D, Cadar D, Zika Virus Infection after Travel to Tahiti , December 2013, Emerg. Infect. Dis. 20 (2014) 8–10.
232 233 234 235	[22]	L. Dupuis-Maguiraga, M. Noret, S. Brun, R. Le Grand, G. Gras, P. Roques, Chikungunya Disease : Infection-Associated Markers from the Acute to the Chronic Phase of Arbovirus-Induced Arthralgia, PLoS Negl. Trop. Dis. 6 (2012). doi:10.1371/journal.pntd.0001446.
236 237	[23]	E. Data4u, Diagnosis of COVID-19 and its clinical spectrum, Kaggle. (2020). https://www.kaggle.com/einsteindata4u/covid19 (accessed April 5, 2020).
238 239 240	[24]	J. Demsar, B. Zupan, G. Leban, T. Curk, Orange : From Experimental Machine Learning, Knowl. Discov. Databases PKDD 2004. (2004) 537–539. doi:10.1007/978-3-540-30116-5_58.

241 242 243	[25]	J. Luts, F. Ojeda, R. Van de Plas Raf, B. De Moor, S. Van Huffel, J.A.K. Suykens, A tutorial on support vector machine-based methods for classification problems in chemometrics, Anal. Chim. Acta. 665 (2010) 129–145.
244		doi:10.1016/j.aca.2010.03.030.
245 246 247 248 249	[26]	H. Chen, J. Guo, C. Wang, F. Luo, X. Yu, W. Zhang, J. Li, D. Zhao, D. Xu, Q. Gong, J. Liao, H. Yang, W. Hou, Y. Zhang, Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records, Lancet. 395 (2020) 809–815. doi:10.1016/S0140-6736(20)30360-3.
250 251 252	[27]	R. Wang, C. Liao, H. He, C. Hu, Z. Wei, Z. Hong, C. Zhang, M. Liao, H. Shui, COVID-19 in Hemodialysis Patients: A Report of 5 Cases, Am. J. Kidney Dis. (2020). doi:10.1053/j.ajkd.2020.03.009.
253 254 255	[28]	F. Ye, S. Xu, Z. Rong, R. Xu, X. Liu, P. Deng, H. Liu, X. Xu, Delivery of infection from asymptomatic carriers of COVID-19 in a familial cluster, Int. J. Infect. Dis. 105 (2020) 72–80. doi:10.1016/j.ijid.2020.03.042.
256 257 258	[29]	G. Ye, Z. Pan, Y. Pan, Q. Deng, L. Chen, J. Li, Y. Li, X. Wang, Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation, J. Infect. (2020) 3–6. doi:10.1016/j.jinf.2020.03.001.
259 260 261 262 263 264	[30]	J.F.W. Chan, S. Yuan, K.H. Kok, K.K.W. To, H. Chu, J. Yang, F. Xing, J. Liu, C.C.Y. Yip, R.W.S. Poon, H.W. Tsoi, S.K.F. Lo, K.H. Chan, V.K.M. Poon, W.M. Chan, J.D. Ip, J.P. Cai, V.C.C. Cheng, H. Chen, C.K.M. Hui, K.Y. Yuen, A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster, Lancet. 395 (2020) 514–523. doi:10.1016/S0140-6736(20)30154-9.
265 266 267 268	[31]	Z. Wang, X. Chen, Y. Lu, F. Chen, W. Zhang, Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment, Biosci. Trends. 14 (2020) 64–68. doi:10.5582/bst.2020.01030.
269 270 271	[32]	P. Yu, J. Zhu, Z. Zhang, Y. Han, L. Huang, A familial cluster of infection associated with the 2019 novel coronavirus indicating potential person-to-person transmission during the incubation period, J. Infect. Dis. (2020) 1–5.

272		doi:10.1093/infdis/jiaa077.
273 274 275	[33]	X. Wang, Z. Zhou, J. Zhang, F. Zhu, Y. Tang, X. Shen, A case of 2019 Novel Coronavirus in a pregnant woman with preterm delivery, Clin. Infect. Dis. (2020). doi:10.1093/cid/ciaa200.
276 277 278 279	[34]	Y. Wu, X. Cui, N. Wu, R. Song, W. Yang, W. Zhang, D. Fan, Z. Chen, J. An, A unique case of human Zika virus infection in association with severe liver injury and coagulation disorders, Sci. Rep. 7 (2017) 1–8. doi:10.1038/s41598-017-11568-4.
280 281 282	[35]	G.H.Y. Leung, R.W. Baird, J. Druce, N.M. Anstey, Zika virus infection in Australia following a monkey bite in Indonesia, Southeast Asian J. Trop. Med. Public Health. 46 (2015) 460–464.
283 284 285 286	[36]	H.C. Jang, W.B. Park, U.J. Kim, J.Y. Chun, S.J. Choi, P.G. Choe, S.I. Jung, Y. Jee, N.J. Kim, E.H. Choi, M.D. Oh, First imported case of Zika virus infection into Korea, J. Korean Med. Sci. 31 (2016) 1173–1177. doi:10.3346/jkms.2016.31.7.1173.
287 288 289 290	[37]	J. Li, C.Y. Chong, N.W. Tan, C.F. Yung, N.W. Tee, K.C. Thoon, Characteristics of Zika Virus Disease in Children: Clinical, Hematological, and Virological Findings from an Outbreak in Singapore, Clin. Infect. Dis. 64 (2017) 1445–1448. doi:10.1093/cid/cix137.
291 292 293	[38]	L.H. Chen, Zika Virus Infection in a Massachusetts Resident After Travel to Costa Rica: A Case Report, Ann. Intern. Med. 164 (2016) 574. doi:10.7326/L16- 0075.
294 295 296	[39]	A.F. Cardona-Cardona, A.J. Rodríguez Morales, Severe abdominal pain in a patient with Zika infection: A case in Risaralda, Colombia, J. Infect. Public Health. 9 (2016) 372–373. doi:10.1016/j.jiph.2016.03.001.
297 298 299 300	[40]	C. Therrien, G. Jourdan, K. Holloway, C. Tremblay, M.A. Drebot, First Imported Case of Chikungunya Virus Infection in a Travelling Canadian Returning from the Caribbean, Can. J. Infect. Dis. Med. Microbiol. 2016 (2016). doi:10.1155/2016/2980297.
301	[41]	G.M. Oliveira, T.M.A. Marques, J.R. Dos Santos, E.D.F. Daher, R.D. Leite, E.S.

302 303 304		Girão, R. da J.P. Neto, Clinical and laboratory profiles of children with sever chikungunya infection, Rev. Soc. Bras. Med. Trop. 52 (2019) 2017–2020. doi:10.1590/0037-8682-0232-2018.
305 306 307 308	[42]	M.M. Aly, S. Ali, A.F. Muianga, V. Monteiro, J.G. Gallego, J. Weyer, K.I. Falk, J.T. Paweska, J. Cliff, E.S. Gudo, Severe Chikungunya infection in Northern Mozambique: a case report, BMC Res. Notes. 10 (2017) 4–9. doi:10.1186/s13104-017-2417-z.
309 310 311 312	[43]	M.C. Schechter, K.A. Workowski, J.K. Fairley, Unusual Presentation of Chikungunya Virus Infection With Concomintant Erysipelas in a Returning Traveler From the Caribbean: A Case Report, Open Forum Infect. Dis. 1 (2014) ofu097–ofu097. doi:10.1093/ofid/ofu097.
313 314 315 316	[44]	J.M. de la Hoz, B. Bayona, S. Viloria, J.L. Accini, H.S. Juan-Vergara, D. Viasus, Fatal cases of Chikungunya virus infection in Colombia: Diagnostic and treatment challenges, J. Clin. Virol. 69 (2015) 27–29. doi:10.1016/j.jcv.2015.05.021.
317 318 319 320 321	[45]	I. Eckerle, V.T. Briciu, Ergönül, M. Lupşe, A. Papa, A. Radulescu, S. Tsiodras, C. Tsitou, C. Drosten, V.R. Nussenblatt, C.B. Reusken, L.A. Sigfrid, N.J. Beeching, Emerging souvenirs—clinical presentation of the returning traveller with imported arbovirus infections in Europe, Clin. Microbiol. Infect. 24 (2018) 240–245. doi:10.1016/j.cmi.2018.01.007.
322 323 324 325 326	[46]	P.Y. Chia, H. Sen Yew, H. Ho, A. Chow, S.P. Sadarangani, M. Chan, Y.W. Kam, C.Y. Chong, K.C. Thoon, C.F. Yung, J.H. Li, D.C. Lye, P.P. De, L.F.P. Ng, T.W. Yeo, Y.S. Leo, Clinical features of patients with Zika and dengue virus co- infection in Singapore, J. Infect. 74 (2017) 611–615. doi:10.1016/j.jinf.2017.03.007.
327 328	[47]	M. Mardani, F. Abbasi, M. Aghahasani, B. Ghavam, First Iranian imported case of dengue, Int. J. Prev. Med. 4 (2013) 1075–1077.
329 330 331	[48]	S. Advani, S. Agarwal, J. Verma, Haemogram profile of dengue fever in adults during 19 September – 12 November 2008: A study of 40 cases from Delhi., Dengue Bull. 35 (2011) 71–75. https://apps.who.int/iris/handle/10665/171014.
332	[49]	D. Ballabio, F. Grisoni, R. Todeschini, Multivariate comparison of classification

333		performance measures, Chemom. Intell. Lab. Syst. 174 (2018) 33-44.
334		doi:10.1016/j.chemolab.2017.12.004.
335 336 337 338	[50]	L. Zeng, S. Xia, W. Yuan, K. Yan, F. Xiao, J. Shao, W. Zhou, Neonatal Early- Onset Infection with SARS-CoV-2 in 33 Neonates Born to Mothers with COVID-19 in Wuhan, China, JAMA Pediatr. 23 (2020) 4–6. doi:10.1001/jamapediatrics.2020.0878.
339 340 341 342 343	[51]	 X. Yang, Y. Yu, J. Xu, H. Shu, J. Xia, H. Liu, Y. Wu, L. Zhang, Z. Yu, M. Fang, T. Yu, Y. Wang, S. Pan, X. Zou, S. Yuan, Y. Shang, Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Respir. Med. 2600 (2020) 1–7. doi:10.1016/S2213-2600(20)30079-5.
344 345	[52]	D. Wu, T. Wu, Q. Liu, Z. Yang, The SARS-CoV-2 outbreak: what we know., Int. J. Infect. Dis. (2020). doi:10.1016/j.ijid.2020.03.004.
346 347 348	[53]	Pan American Health Organization (PAHO), Tool for the diagnosis and care of patients with suspected arboviral diseases, 2017. http://iris.paho.org/xmlui/handle/123456789/33895.
349 350 351 352 353 354	[54]	E.L. Azeredo, F.B. dos Santos, L.S. Barbosa, T.M.A. Souza, J. Badolato-Corrêa, J.C. Sánchez-Arcila, P.C.G. Nunes, L.M. de-Oliveira-Pinto, A.M. de Filippis, M. Dal Fabbro, I. Hoscher Romanholi, R. Cunha, Clinical and Laboratory Profile of Zika and Dengue Infected Patients: Lessons Learned From the Co-circulation of Dengue, Zika and Chikungunya in Brazil, PLoS Curr. (2018) 1–20. doi:10.1371/currents.outbreaks.0bf6aeb4d30824de63c4d5d745b217f5.
355 356 357	[55]	R. Li, J. Ding, G. Ding, X. Fan, Y. He, X. Wang, H. Zhang, J. Ji, H. Li, Zika virus infections, a review, Radiol. Infect. Dis. 4 (2017) 88–93. doi:10.1016/j.jrid.2017.01.002.
358 359 360 361	[56]	S.L. Beltrán-Silva, S.S. Chacón-Hernández, E. Moreno-Palacios, J.Á. Pereyra- Molina, Clinical and differential diagnosis: Dengue, chikungunya and Zika, Rev. Médica Del Hosp. Gen. México. 81 (2018) 146–153. doi:10.1016/j.hgmx.2016.09.011.
362 363	[57]	E.M. Ellis, T.M. Sharp, J. Pérez-Padilla, L. González, B.K. Poole-Smith, E. Lebo, C. Baker, M.J. Delorey, B. Torres-Velasquez, E. Ochoa, B. Rivera-Garcia,

16

364		H. Díaz-Pinto, L. Clavell, A. Puig-Ramos, G.E. Janka, K.M. Tomashek,
365		Incidence and Risk Factors for Developing Dengue-Associated Hemophagocytic
366		Lymphohistiocytosis in Puerto Rico, 2008 - 2013, PLoS Negl. Trop. Dis. 10
367		(2016) 2008–2013. doi:10.1371/journal.pntd.0004939.
368	[58]	T.M. Sharp, L. Gaul, A. Muehlenbachs, E. Hunsperger, J. Bhatnagar, R.
369		Lueptow, G.A. Santiago, J.L. Muñoz-Jordan, D.M. Blau, P. Ettestad, J.D. Bissett,
370		S.C. Ledet, S.R. Zaki, K.M. Tomashek, Fatal hemophagocytic
371		lymphohistiocytosis associated with locally acquired dengue virus infection -
372		New Mexico and Texas, 2012, Morb. Mortal. Wkly. Rep. 63 (2014) 49-54.
373		doi:10.1016/j.annemergmed.2014.04.007.
374		